Investigating the effect of oxytocin on pancreatic endocrine functions by determining glucagon secretion during hypoglycemia in participants with type 1 diabetes.
Glucagonotropic effects of oxytocin will be examined in 16 participants with type 1 diabetes, during a hypoglycaemic clamp with concomitant intravenous infusion of synthetic oxytocin or placebo in a randomised, double-blinded design. This will determine the effect of oxytocin on the glucagon response to hypoglycemia. Additional changes in plasma/serum concentrations of insulin, C-peptide, glucose, glucose-dependent insulinotropic polypeptid (GIP) and glucagon-like peptide 1 (GLP-1) will be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
16
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Denmark
Glucagon secretion
Glucagon secretion, measured as the difference in plasma glucagon response to hypoglycaemia (as assessed by baseline subtracted area under curve (bsAUC)) during the hypoglycaemic clamp, between study days with oxytocin and with placebo
Time frame: From time 30 to time 90 minutes
Glucagon during recovery
measured as difference in glucagon bsAUC in the recovery phase
Time frame: From time 90 minutes to time 135 minutes
Glucagon during the entire period
measured as difference in glucagon bsAUC in the intire period
Time frame: From time 0 minutes to time 135 minutes
Glucose infusion
measured as the total amount of glucose infused
Time frame: From time 0 minutes to time 135 minutes
Insulin
measured as the difference in circulating levels of insulin between study days
Time frame: From time 0 minutes to time 135 minutes
c-peptide
measured as the difference in circulating levels of c-peptide between study days
Time frame: From time 0 minutes to time 135 minutes
Epinephrine
measured as the difference in circulating levels of epinephrine between study days
Time frame: From time 0 minutes to time 135 minutes
Norepinephrine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
measured as the difference in circulating levels of norepinephrine between study days
Time frame: From time 0 minutes to time 135 minutes
Cortisol
measured as the difference in circulating levels of cortisol between study days
Time frame: From time 0 minutes to time 135 minutes
Cross-linked C-telopeptide of type I collagen( CTX)
measured as the difference in circulating levels of CTX between study days
Time frame: From time 0 minutes to time 135 minutes
Procollagen type I N-terminal propeptide (P1NP)
measured as the difference in circulating levels of P1NP between study days
Time frame: From time 0 minutes to time 135 minutes
Growth Hormone (GH)
measured as the difference in circulating levels of GH between study days
Time frame: From time 0 minutes to time 135 minutes